Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 27, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares, executed under authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 2,750,000 ordinary shares of 25 pence each.
- Purchase Price: 1,115.66 pence per share.
- Treasury Holdings: Following cancellation, the company holds 474,194,158 shares in Treasury, representing 8.96% of total voting rights.
- Shares in Issue: 5,290,289,849 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,750,000 shares. This action increased the proportion of Treasury shares held by the company to 8.96% of total voting rights. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding the share buyback.
Investor Verification Checklist
- Verify the total cost of the repurchase (2,750,000 shares x 1,115.66 pence) against the company's cash position in broader financial reports.
- Confirm the updated total voting rights denominator (5,290,289,849 shares) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Review the Annual General Meeting minutes from May 21, 2008, to understand the full scope of the share buyback authority granted.